Israeli pharmaceutical company Can-Fite BioPharma Ltd. has announced that it has raised NIS 26.5 million ($7.2 million) in its secondary offering on the Tel Aviv stock exchange. The company says that it will direct the funds towards a phase II/III clinical trial of its psoriasis treatment.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments